We found in this study that the prevalence of FSD in rheumatoid arthritis in our centers was 29.4%. Age and family dynamics appear to be more important predictors compared to disease activity.
Aim: This is a rheumatoid arthritis (RA) descriptive study, the first of its kind carried out in Malaysia. Methods: This descriptive study involved 1084 RA patients’ epidemiological and clinical data taken from Selayang, Putrajaya, Taiping and Seremban hospitals from June 2004 to December 2005. Results: One thousand and eighty‐four RA patients'data were analysed; 960 (88.6%) patients were female and 124 (11.4%) were male, approximately 8 : 1 M : F ratio. The majority of the patients were Indian (591; 54.5%), followed by the Malays (340; 31.4%), Chinese (126; 11.6%), indigenous (13; 1.2%) and others (14; 1.3%). Mean age was 49.6 ± 11.8 years with the youngest being 15 years and the oldest 88 years of age. Mean age for males was 52.0 ± 12.0 and females 49.3 ± 11.7 years (P = 0.017). Most of these patients were housewives (565; 52.1%), followed by paid workers (266; 24.5%), retired patients (80; 7.4%), unemployed (76; 7.0%) and others (97; 8.9%). Mean duration of illness was 8.4 ± 6.7 years; 805 (74.3%) patients were relatively new patients (≤ 2 years illness duration) and 279 (25.7%) patients had illness duration > 2 years. Eight hundred and six (74.4%) were seropositive RA patients and 385 (35.5%) had presence of deformity. The majority of patients were treated with methotrexate (178; 16.4%), followed by combination of methotrexate, sulfasalazine and hydroxychloroquine (143; 13.2%), leflunomide (140; 12.9%), sulfasalazine (133; 12.3%) and combination of methotrexate and sulfasalazine (108; 10%). Conclusion: In the above study, the majority of patients were female (960; 88.6%), Indian (591; 54.5%), had a mean age of 49.6 ± 11.8 years, most were housewives with a mean duration of illness of 8.4 ± 6.7 years and were treated with methotrexate (178; 16.4%). The results of the study may help Malaysian rheumaologists to understand their patients better and treat RA holistically.
Introduction: This cross sectional study consisted of taking anti-Citrulinated Cyclic Peptide CCP levels and doing Health Assessment Questionnaire for Rheumatoid Arthritis patients. 52 rheumatoid arthritis patients were recruited. Objective: To investigate the correlation between anti-Citrulinated Cyclic Peptide levels and Health Assessment Questionnaire severity among rheumatoid arthritis patients. Results: 52 RA patients were recruited. 43(82.7%) patients were female and 9(17.3%) were male. 43(82.7%) patients were Malay, 2(3.8%) patients were Chinese, 6(11.5%) patients were Indian and 1(1.9%) patient was Sikh. Mean age was 46.17±12.66 years and the 41-60 age group has the most patients (30(47.1%)). Mean age of onset was 43.24±12.72 years and mean disease duration was 3.08±4.49 years. 30(58.8%) patients did not have any complications, 13(25.5%) had secondary osteoarthritis, 4(7.8%) had lungs complications, 2(3.9%) had hepatitis, 1(2.0%) had nephropathy and 1(2.0%) had Cushing's syndrome. 25(49.0%) of the patients had deformities. 33(67.4%) patients were still active with a mean DAS28 score of 4.3±2.0 and 16(32.7%) had complete remission with a mean DAS28 score of 1.6±0.8. The anti-Citrulinated Cyclic Peptide median value was 10768.17±48342.30. IU/ml and the median total Health Assessment Questionnaire score was 1.50±1.25. Pearson correlation analysis revealed statistical significant correlation between Health Assessment Questionnaire severity and anti-Citrulinated Cyclic Peptide levels (p=0.039) and Health Assessment Questionnaire score and anti-Citrulinated Cyclic Peptide levels (p=0.016). Conclusion: There was significant correlation between Health Assessment Questionnaire severity and anti-Citrulinated Cyclic Peptide levels.
No abstract
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.